Forecast
Period
|
2026-2030
|
Market
Size (2024)
|
USD
1.55 Billion
|
Market
Size (2030)
|
USD
2.39 Billion
|
CAGR
(2025-2030)
|
7.45%
|
Fastest
Growing Segment
|
Kits
|
Largest
Market
|
North
America
|
Market Overview
Global Ferritin Testing Market was valued
at USD 1.55 Billion in 2024 and is expected to reach USD 2.39 Billion by 2030
with a CAGR of 7.45% during the forecast period. The global ferritin testing
market is driven by several key factors, including the rising prevalence of
iron deficiency anemia and other iron-related disorders. Ferritin testing is
crucial for diagnosing and monitoring these conditions, as it provides insights
into iron storage levels in the body. Increasing awareness about the importance
of early diagnosis and management of iron deficiency, particularly in
vulnerable populations such as pregnant women and children, is contributing to
the market growth. Advancements in diagnostic technology, such as
high-throughput testing methods and point-of-care testing, are also making
ferritin testing more accessible and efficient. The growing demand for personalized
medicine and regular health check-ups is fueling the adoption of ferritin
testing globally, driving market expansion.
Key Market Drivers
Rising
Prevalence of Iron Deficiency & Anemia
The global prevalence of iron deficiency and iron deficiency anemia is a key
driver propelling the growth of the ferritin testing market. Iron deficiency
anemia is a major public health concern worldwide, particularly affecting
vulnerable populations such as pregnant women, young children, and individuals
living in developing countries where access to proper nutrition may be limited.
In 2021, globally, 31.2% of women were affected by anemia, compared to
17.5% of men. The gender gap was particularly evident during the reproductive
years, between the ages of 15 and 49. In this age group, the prevalence of
anemia in women was 33.7%, while it was significantly lower in men at 11.3%.
According to the World Health
Organization (WHO), iron deficiency anemia affects a significant portion of the
global population, with estimates suggesting that nearly one-quarter of the
world’s population suffers from this condition. Ferritin, a protein that stores
iron in the body, serves as a reliable biomarker for determining iron levels.
When iron levels drop due to inadequate intake or absorption, ferritin levels
also fall. Ferritin testing has become essential in diagnosing and managing
iron deficiency anemia, as it allows healthcare providers to identify the
condition in its early stages and take appropriate action. As awareness of the
importance of early diagnosis and management grows, healthcare systems are
increasingly adopting ferritin testing as a standard tool for assessing iron
levels. In particular, high-risk groups such as pregnant women and children
require regular monitoring of ferritin levels to prevent the detrimental
effects of iron deficiency, which can lead to fatigue, impaired cognitive
development, and reduced immune function. The rising burden of iron deficiency
anemia in emerging and developed markets alike contributes significantly to the
growth of the ferritin testing market.
Increased
Focus on Preventive Healthcare and Early Diagnosis
As healthcare systems worldwide shift towards preventive care and early
intervention, there has been a notable increase in the emphasis on diagnosing
conditions such as iron deficiency anemia at an early stage. Ferritin testing
plays a critical role in early diagnosis, allowing for the timely
identification of low iron stores before they develop into full-blown anemia.
Preventive healthcare is becoming a priority in many developed nations, where healthcare
systems are looking for ways to reduce long-term healthcare costs and improve
population health outcomes. Iron deficiency, if left untreated, can lead to
serious health complications, including reduced cognitive function, chronic
fatigue, weakened immune response, and in severe cases, complications during
pregnancy and childbirth. With the growing awareness that early diagnosis and
treatment of iron deficiency anemia can prevent these outcomes, there is an
increasing demand for ferritin testing as a preventive measure. Healthcare
providers are increasingly recommending ferritin tests as part of routine
health check-ups, particularly for high-risk populations such as pregnant
women, children, and individuals with chronic diseases such as gastrointestinal
disorders, where absorption of iron may be impaired. The shift toward proactive
healthcare and the increasing focus on early diagnosis are significant factors
contributing to the growing adoption of ferritin testing across the global
market.
Growing
Awareness of Iron Deficiency in Vulnerable Populations
There has been a growing awareness of iron deficiency, particularly among
vulnerable populations such as pregnant women, young children, the elderly, and
individuals with chronic diseases. Pregnant women are especially at risk of
developing iron deficiency anemia due to the increased iron demands of both the
mother and the developing fetus. Iron deficiency during pregnancy can lead to
preterm birth, low birth weight, and developmental delays in infants. In young
children, iron deficiency can affect cognitive development, leading to learning
difficulties and behavioral problems. The increasing awareness of these risks
has prompted healthcare organizations, governments, and nonprofit groups to raise
awareness about the importance of monitoring iron levels and preventing iron
deficiency in these vulnerable groups. As more individuals seek early diagnosis
and treatment, the demand for ferritin testing has risen significantly.
Healthcare providers are increasingly recommending ferritin testing as part of
routine screenings for pregnant women, children, and the elderly to ensure that
iron levels are within the healthy range. Educational campaigns aimed at
promoting healthy eating habits, especially in regions with limited access to
iron-rich foods, have further increased awareness of iron deficiency and its
potential consequences. This heightened awareness and the subsequent demand for
ferritin testing are driving market growth, especially in areas where iron
deficiency is prevalent, such as developing countries and areas with limited
access to healthcare.
Expanding
Applications in Clinical and Research Settings
Ferritin testing is gaining increased recognition not only in clinical
diagnostics but also in research settings. Researchers are exploring the use of
ferritin levels as biomarkers in various conditions, including cancer,
cardiovascular diseases, and metabolic disorders. A researcher
from Aston University has developed a groundbreaking technique using light that
could transform non-invasive medical diagnostics and optical communication. The study demonstrates how a type of
light, known as Orbital Angular Momentum (OAM), can be utilized to enhance
imaging and data transmission through skin and other biological tissues. Led by
Professor Igor Meglinski, the team discovered that OAM light offers
unparalleled sensitivity and precision, potentially eliminating the need for
procedures like surgery or biopsies. Moreover, this advancement could allow
doctors to monitor disease progression and devise more effective treatment
strategies.
Elevated ferritin levels have been
associated with several inflammatory conditions, making it a useful marker in
the study of inflammation and immune response. In oncology, ferritin levels are
being studied as potential indicators of cancer prognosis, particularly in
cancers such as breast and liver cancer. As research into ferritin’s role in
various diseases expands, so does the use of ferritin testing in clinical
trials and research studies. This growing application of ferritin testing in
clinical and research settings is broadening the market’s scope and increasing
its relevance in the global healthcare ecosystem. Pharmaceutical companies and
biotech firms are increasingly utilizing ferritin testing in their research
processes to better understand disease mechanisms and develop more targeted
therapies. As more applications for ferritin testing are identified in clinical
and research contexts, the demand for these tests is expected to rise, further
contributing to market growth.
Increase
in Chronic Diseases and Disorders Impacting Iron Absorption
The rise in chronic diseases and disorders that affect iron absorption, such as
gastrointestinal disorders, chronic kidney disease, and malabsorption
syndromes, is another significant driver of the global ferritin testing market.
Conditions like celiac disease, Crohn’s disease, and ulcerative colitis can
impair the body’s ability to absorb iron from food, leading to iron deficiency.
Chronic kidney disease, which is becoming more prevalent globally, can also
interfere with iron metabolism and lead to anemia. According to CDC, current
estimates indicate that chronic kidney disease (CKD) is more prevalent in
individuals aged 65 years or older, affecting 34% of this age group, compared
to 12% in those aged 45–64 years and 6% in individuals aged 18–44 years.
Additionally, CKD is slightly more common in women, with a prevalence of 14%,
compared to 12% in men. The disease is also more prevalent among non-Hispanic
Black adults, affecting 20% of this group, as compared to 14% in non-Hispanic
Asian adults and 12% in non-Hispanic White adults.
As the global prevalence of these
chronic conditions rises, the need for ferritin testing to monitor iron levels
in affected individuals is growing. Healthcare providers use ferritin testing
to assess iron stores in patients with these conditions to ensure that they
receive the appropriate treatment, such as iron supplementation or iron
therapy. With the increasing number of individuals living with chronic diseases
that impact iron absorption, ferritin testing has become a vital tool in
managing these conditions, further driving demand for ferritin testing
solutions.
Download Free Sample Report
Key Market Challenges
High
Cost of Advanced Diagnostic Equipment
One of the major challenges in the global ferritin testing market is the high
cost associated with advanced diagnostic equipment and testing platforms.
Sophisticated ferritin testing systems, such as automated analyzers and
high-throughput platforms, can be expensive to acquire and maintain. This
financial burden can deter small healthcare providers, laboratories, and
diagnostic centers, particularly in low- and middle-income regions, from
adopting these advanced testing technologies. The initial investment required
to purchase and install such equipment may limit accessibility to ferritin
testing, especially in underdeveloped regions where financial resources are
constrained. Consequently, healthcare providers in these areas may rely on less
advanced, manual testing methods that are more time-consuming and less
accurate, leading to lower adoption of ferritin testing solutions. This
economic barrier could restrict the growth of the ferritin testing market,
particularly in price-sensitive regions.
Limited
Awareness and Accessibility in Rural and Underserved Areas
While ferritin testing is widely recognized as an essential diagnostic tool,
access to such testing is often limited in rural and underserved regions,
particularly in developing countries. Lack of awareness about iron deficiency
and its potential consequences, combined with inadequate healthcare
infrastructure, results in limited access to ferritin testing in these regions.
In many rural and low-income areas, diagnostic labs may not have the necessary
equipment, resources, or trained personnel to conduct ferritin tests, leading
to a delay in diagnosis and treatment of iron deficiency anemia. The absence of
point-of-care (POC) testing options in these regions further complicates
matters, as patients may need to travel long distances to access ferritin
testing, making it less accessible to those who need it most. Addressing this
challenge requires greater investment in healthcare infrastructure, awareness
campaigns, and the availability of affordable, easy-to-use diagnostic tools in
underserved areas.
Regulatory
and Standardization Challenges
Another significant challenge faced by the ferritin testing market is the
regulatory and standardization hurdles associated with diagnostic tests. The
medical diagnostics industry is subject to strict regulations and quality
control standards enforced by regulatory bodies such as the U.S. Food and Drug
Administration (FDA), the European Medicines Agency (EMA), and the World Health
Organization (WHO). Ferritin testing solutions must meet these regulatory
standards before they can be commercially distributed. However, the approval
process for new diagnostic technologies can be lengthy and expensive,
particularly for novel or innovative ferritin testing devices. The lack of
uniformity in regulations across different regions can make it difficult for
manufacturers to standardize their products for global markets, potentially
hindering the adoption of ferritin testing on a broader scale. This regulatory
complexity can slow down the market’s growth and create barriers to entry for
new players, especially in regions with less developed regulatory frameworks.
Key Market Trends
Technological
Integration in Point-of-Care Testing
The integration of
ferritin testing into point-of-care (POC) diagnostic devices is a critical
factor
driving the market.
Point-of-care testing enables rapid and convenient results for patients,
particularly in rural or underserved areas where access to advanced laboratory
testing may be limited. Innovations in POC technology, such as portable
ferritin testing devices and home-use kits, allow individuals to monitor their
ferritin levels without the need to visit a healthcare facility. In August
2024, Engineers at Monash have created a groundbreaking
finger-prick blood test with remarkable precision, akin to finding a
"needle in a haystack," to detect key protein biomarkers in the early
stages of Alzheimer's disease (AD) before symptoms manifest. Roughly the size of a credit card, this
test utilizes innovative, patented sensor technology capable of identifying
extremely low concentrations of disease markers in blood within minutes. With
the number of Australians diagnosed with dementia expected to double by 2054,
this fast and non-invasive blood test could play a crucial role in improving
diagnosis processes, offering general practitioners unprecedented access to
efficient diagnostic tools.
This is particularly beneficial for
individuals in remote areas or those with limited access to healthcare
services. The rise of telemedicine and home healthcare services has further
accelerated the adoption of POC ferritin testing devices, as patients can use
these tools to monitor their health at home and consult with healthcare
professionals remotely. The growing demand for at-home health monitoring
devices and the ability to perform ferritin tests on-site or at home are
helping to drive the growth of the ferritin testing market.
Advancements
in Diagnostic Technologies
Technological advancements in diagnostic tools have greatly impacted the
ferritin testing market, making tests more efficient, accurate, and accessible.
Traditional ferritin testing methods, such as enzyme-linked immunosorbent assay
(ELISA) and immunoassays, have evolved with the introduction of high-throughput
testing technologies that can process large volumes of samples with greater
precision and speed. These advancements allow healthcare providers to perform
multiple tests at once, which is especially important in large hospital
settings and diagnostic laboratories where quick and accurate results are
crucial for patient care. The advent of automated ferritin testing platforms
has further streamlined the testing process, minimizing human error and
reducing the time it takes to receive results. Point-of-care (POC) testing
technology has also made significant strides, enabling patients to be tested
for ferritin levels outside traditional laboratory environments. This is
particularly useful in remote areas where laboratory access may be limited, as
well as in situations where immediate results are necessary for timely
intervention. The rise of wearable diagnostic devices and at-home testing kits
for ferritin levels is another aspect of technological innovation that is
making ferritin testing more accessible. These advancements not only improve
the accuracy of test results but also contribute to greater convenience and
flexibility for both patients and healthcare providers, ultimately expanding
the adoption of ferritin testing across the globe.
Segmental Insights
Product Insights
Based on the product, kits are currently
dominating the market. Ferritin testing kits have become the preferred choice
due to their convenience, cost-effectiveness, and ease of use. These kits
typically contain all the necessary components, including reagents, standards,
and controls required for conducting ferritin tests. They are particularly
popular in both clinical laboratories and point-of-care settings, as they allow
healthcare providers to conduct tests quickly and efficiently without the need
for specialized equipment. Kits are also more affordable compared to standalone
instruments, making them a cost-effective solution for many healthcare
facilities, particularly in developing countries where financial resources may
be limited.
The growing adoption of ferritin testing
kits is driven by the increasing demand for fast and reliable diagnostic
solutions for iron deficiency and anemia. These kits are widely used for
screening patients at risk of iron deficiency, including pregnant women,
children, and individuals with chronic diseases. The ease of use associated
with these kits also facilitates their use in various healthcare environments,
ranging from large hospitals and diagnostic laboratories to smaller clinics and
even home settings. As the healthcare landscape shifts toward decentralized
testing and point-of-care solutions, ferritin testing kits have seen increasing
adoption for their ability to deliver rapid results without the need for
complex instrumentation. The convenience of ferritin testing kits extends to
their portability, which is particularly important in regions with limited
access to advanced medical infrastructure. In rural or underserved areas, where
laboratory facilities may be scarce, ferritin testing kits provide an
affordable and accessible solution to detect iron deficiency and anemia. The
ability to carry out ferritin testing on-site allows healthcare providers to
identify and address iron deficiency more promptly, leading to better patient
outcomes.
End Use Insights
Based on the end use segment, Hospitals
are currently dominating the global ferritin testing market over diagnostic
laboratories. This is primarily due to the high volume of patients treated in
hospital settings and the growing need for in-hospital diagnostic testing for
conditions like iron deficiency anemia. Hospitals, being the primary healthcare
providers for a wide range of medical conditions, are heavily reliant on
accurate and rapid diagnostic tests to support effective patient care. Ferritin
testing is commonly performed in hospitals to diagnose iron deficiency,
particularly in high-risk groups such as pregnant women, children, the elderly,
and individuals with chronic diseases or nutritional deficiencies. As hospitals
treat a broad spectrum of patients with varying conditions, the demand for
ferritin testing is consistent and expansive, making hospitals the dominant
segment in the market.
In addition, hospitals typically have
more advanced diagnostic infrastructure, including automated systems for
laboratory tests, which can handle large volumes of ferritin testing. The
integration of ferritin testing within the broader diagnostic services offered
by hospitals ensures that patients receive timely and efficient care. Many
hospitals have specialized departments such as hematology and immunology, where
ferritin testing plays a crucial role in diagnosing iron metabolism disorders,
including anemia, liver diseases, and chronic inflammatory conditions. This
wide range of applications enhances the frequency and importance of ferritin
testing in hospitals. Hospitals also benefit from the convenience of having
ferritin testing and other diagnostic services in-house, as it speeds up the
process of patient care. This is particularly critical in emergency situations
where immediate results are required to make important clinical decisions, such
as diagnosing anemia in a pregnant patient or identifying iron deficiency in an
elderly patient. Hospitals are also better positioned to conduct follow-up
tests and provide timely interventions based on ferritin levels, making it a
preferred setting for performing these tests.
Download Free Sample Report
Regional Insights
North
America was the dominant region in the global ferritin testing market.
Several factors contribute to North America’s leadership in the market,
including advanced healthcare infrastructure, high levels of awareness about
iron deficiency and anemia, and the increasing prevalence of chronic conditions
that require regular ferritin testing. The United States and Canada, in
particular, have well-established healthcare systems that support the
widespread use of ferritin testing in hospitals, diagnostic laboratories, and
point-of-care settings. In North America, ferritin testing is routinely
performed as part of standard diagnostic protocols, especially for at-risk
populations, such as pregnant women, children, and individuals with chronic
diseases like gastrointestinal disorders, which may affect iron absorption.
The
region also benefits from a high level of healthcare spending and access to
cutting-edge diagnostic technologies, including automated ferritin testing
platforms and point-of-care devices. North American countries, especially the
U.S., have a well-developed market for medical devices and diagnostics, and the
adoption of advanced ferritin testing solutions is widespread. This has driven
the demand for ferritin testing in both clinical and research settings, as
healthcare providers and institutions look to provide timely and accurate
diagnoses for conditions like iron deficiency anemia, chronic diseases, and
liver disorders, which are commonly associated with altered ferritin levels. Another
factor contributing to North America's dominance is the increasing focus on
preventive healthcare and early diagnosis. As healthcare systems in the region
increasingly emphasize early detection of health conditions to prevent costly
long-term treatments, ferritin testing has become an essential diagnostic tool.
For example, the rising awareness of iron deficiency in vulnerable populations
like pregnant women and children has led to a greater emphasis on routine
screenings and early intervention, further boosting the demand for ferritin
testing.
Recent Developments
- In November 2024, At the Haematocon 2024
conference in Nagpur, India, Hemex Health unveiled new product offerings for
its Gazelle™ Diagnostic Device, aimed at enhancing diagnostic accessibility for
at-risk populations in difficult environments.
- In January 2025, London Blood Tests is
excited to introduce its new "Healthy Generations Check-Up," a
comprehensive health screening program designed to address the varied needs of
families across all ages. This innovative check-up package focuses on detecting
and managing health conditions from childhood to adulthood, prioritizing
preventative care and early diagnosis.
- In May 2024, JW Pharmaceutical announced
on Thursday that its high-dose iron injectable, Ferinject (ferric
carboxymaltose), will be included in health insurance coverage starting this
month. This marks the first time in 13 years that Ferrinject, which was
launched in March 2011, has been added to the health insurance coverage
registry.
- In June 2023, Well announced on June 22 a
partnership with rapid test supplier 2San to launch 11 "self-diagnostic
tests" across 492 of its 750 stores starting Monday, June 26. The company
stated that this initiative will provide more people across the UK with access
to affordable and accurate in vitro diagnostic tests, supported by expert
pharmacists.
Key Market Players
- Eurolyser Diagnostica GmbH
- Cortez Diagnostics Inc.
- Thermo Fisher Scientific Inc.
- Biomérieux S.A
- Aviva Systems Biology Corporation
- Abnova Corporation
- CTK Biotech Inc.
- Randox Laboratories Ltd.
- Guangzhou Wondfo Biotech Co., Ltd.
- F. Hoffmann-La Roche Ltd.
By
Product
|
By
Application
|
By
End Use
|
By
Region
|
|
- Anaemia
- Hemochromatosis
- Lead
Poisoning
- Pregnancy
- Others
|
- Hospitals
- Diagnostic
Laboratories
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the
Global Ferritin Testing Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
·
Ferritin Testing Market, By Product:
o
Instrument
o
Reagent
o
Kits
·
Ferritin Testing Market, By Application:
o
Anaemia
o
Hemochromatosis
o
Lead Poisoning
o
Pregnancy
o
Others
·
Ferritin Testing Market, By End Use:
o
Hospitals
o
Diagnostic Laboratories
· Ferritin Testing Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Ferritin Testing Market.
Available Customizations:
Global
Ferritin Testing market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
Global Ferritin Testing Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at sales@techsciresearch.com